290 related articles for article (PubMed ID: 37450324)
1. Discovery of BI 7446: A Potent Cyclic Dinucleotide STING Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer.
Kuttruff CA; Fleck M; Carotta S; Arnhof H; Bretschneider T; Dahmann G; Gremel G; Grube A; Handschuh S; Heimann A; Hofmann MH; Impagnatiello MA; Nar H; Rast G; Schaaf O; Schmidt E; Oost T
J Med Chem; 2023 Jul; 66(14):9376-9400. PubMed ID: 37450324
[TBL] [Abstract][Full Text] [Related]
2. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
[TBL] [Abstract][Full Text] [Related]
3. Design, Synthesis and Biological Evaluation of (2',5' and 3'5'-Linked) cGAMP Analogs that Activate Stimulator of Interferon Genes (STING).
Xie X; Liu J; Wang X
Molecules; 2020 Nov; 25(22):. PubMed ID: 33198423
[TBL] [Abstract][Full Text] [Related]
4. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
[TBL] [Abstract][Full Text] [Related]
5. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
6. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
[TBL] [Abstract][Full Text] [Related]
7. STING Activation and its Application in Immuno-Oncology.
Lian Y; Duffy KJ; Yang J
Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
[TBL] [Abstract][Full Text] [Related]
8. Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy.
Sun X; Zhang Y; Li J; Park KS; Han K; Zhou X; Xu Y; Nam J; Xu J; Shi X; Wei L; Lei YL; Moon JJ
Nat Nanotechnol; 2021 Nov; 16(11):1260-1270. PubMed ID: 34594005
[TBL] [Abstract][Full Text] [Related]
9. Discovery of MK-1454: A Potent Cyclic Dinucleotide Stimulator of Interferon Genes Agonist for the Treatment of Cancer.
Chang W; Altman MD; Lesburg CA; Perera SA; Piesvaux JA; Schroeder GK; Wyss DF; Cemerski S; Chen Y; DiNunzio E; Haidle AM; Ho T; Kariv I; Knemeyer I; Kopinja JE; Lacey BM; Laskey J; Lim J; Long BJ; Ma Y; Maddess ML; Pan BS; Presland JP; Spooner E; Steinhuebel D; Truong Q; Zhang Z; Fu J; Addona GH; Northrup AB; Parmee E; Tata JR; Bennett DJ; Cumming JN; Siu T; Trotter BW
J Med Chem; 2022 Apr; 65(7):5675-5689. PubMed ID: 35332774
[TBL] [Abstract][Full Text] [Related]
10. Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I
Wolf NK; Blaj C; Picton LK; Snyder G; Zhang L; Nicolai CJ; Ndubaku CO; McWhirter SM; Garcia KC; Raulet DH
Proc Natl Acad Sci U S A; 2022 May; 119(22):e2200568119. PubMed ID: 35588144
[TBL] [Abstract][Full Text] [Related]
11. STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice.
Skouboe MK; Knudsen A; Reinert LS; Boularan C; Lioux T; Perouzel E; Thomsen MK; Paludan SR
PLoS Pathog; 2018 Apr; 14(4):e1006976. PubMed ID: 29608601
[TBL] [Abstract][Full Text] [Related]
12. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
13. Structure-Activity Relationship Study of Amidobenzimidazole Analogues Leading to Potent and Systemically Administrable Stimulator of Interferon Gene (STING) Agonists.
Song Z; Wang X; Zhang Y; Gu W; Shen A; Ding C; Li H; Xiao R; Geng M; Xie Z; Zhang A
J Med Chem; 2021 Feb; 64(3):1649-1669. PubMed ID: 33470814
[TBL] [Abstract][Full Text] [Related]
14. High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege.
Ager CR; Boda A; Rajapakshe K; Lea ST; Di Francesco ME; Jayaprakash P; Slay RB; Morrow B; Prasad R; Dean MA; Duffy CR; Coarfa C; Jones P; Curran MA
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34341132
[TBL] [Abstract][Full Text] [Related]
15. Nanoparticle delivery improves the pharmacokinetic properties of cyclic dinucleotide STING agonists to open a therapeutic window for intravenous administration.
Wehbe M; Wang-Bishop L; Becker KW; Shae D; Baljon JJ; He X; Christov P; Boyd KL; Balko JM; Wilson JT
J Control Release; 2021 Feb; 330():1118-1129. PubMed ID: 33189789
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel Thieno[2,3-d]imidazole derivatives as agonists of human STING for antitumor immunotherapy using systemic administration.
Niu J; Bai H; Li Z; Gao Y; Zhang Y; Wang X; Yang Y; Xu Y; Geng M; Xie Z; Zhou B
Eur J Med Chem; 2022 Aug; 238():114482. PubMed ID: 35671593
[TBL] [Abstract][Full Text] [Related]
17. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
Corrales L; Glickman LH; McWhirter SM; Kanne DB; Sivick KE; Katibah GE; Woo SR; Lemmens E; Banda T; Leong JJ; Metchette K; Dubensky TW; Gajewski TF
Cell Rep; 2015 May; 11(7):1018-30. PubMed ID: 25959818
[TBL] [Abstract][Full Text] [Related]
18. Design of amidobenzimidazole STING receptor agonists with systemic activity.
Ramanjulu JM; Pesiridis GS; Yang J; Concha N; Singhaus R; Zhang SY; Tran JL; Moore P; Lehmann S; Eberl HC; Muelbaier M; Schneck JL; Clemens J; Adam M; Mehlmann J; Romano J; Morales A; Kang J; Leister L; Graybill TL; Charnley AK; Ye G; Nevins N; Behnia K; Wolf AI; Kasparcova V; Nurse K; Wang L; Puhl AC; Li Y; Klein M; Hopson CB; Guss J; Bantscheff M; Bergamini G; Reilly MA; Lian Y; Duffy KJ; Adams J; Foley KP; Gough PJ; Marquis RW; Smothers J; Hoos A; Bertin J
Nature; 2018 Dec; 564(7736):439-443. PubMed ID: 30405246
[TBL] [Abstract][Full Text] [Related]
19. SHR1032, a novel STING agonist, stimulates anti-tumor immunity and directly induces AML apoptosis.
Song C; Liu D; Liu S; Li D; Horecny I; Zhang X; Li P; Chen L; Miller M; Chowdhury R; Issa M; Shen R; Yan Y; Zhang F; Zhang L; Zhang L; Bai C; Feng J; Zhuang L; Zhang R; Li J; Wilkinson H; Liu J; Tao W
Sci Rep; 2022 May; 12(1):8579. PubMed ID: 35595822
[TBL] [Abstract][Full Text] [Related]
20. Combination of STING agonist with anti-vascular RGD-(KLAKLAK)
Czapla J; Drzyzga A; Ciepła J; Matuszczak S; Jarosz-Biej M; Pilny E; Cichoń T; Smolarczyk R
Cancer Immunol Immunother; 2024 Jun; 73(8):148. PubMed ID: 38832958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
